2 results
Approved WMORecruiting
To evaluate the effect of AZD4831 as compared to placebo on the time to first COPDCompEx event in participants with moderate to severe COPD.
Approved WMORecruiting
Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or persistent disease and Cohort 2 - LN-145 monotherapy in patients previously treated with an antiprogrammedcell death…